Keros Therapeutics, Inc. (KROS) Operating margin 2019–2025
Keros Therapeutics, Inc. (KROS) operating margin by fiscal year — reported operating income divided by reported revenue.
27.7%FY2025 · since FY2019: -105.6% → 27.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 27.7% | +5966.6 pp |
| FY2024 | -5939.0% | +106604.8 pp |
| FY2023 | -112543.7% | — |
| FY2021 | -280.5% | — |
| FY2019 | -105.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More KROS financial trends
KROS RevenueKROS Net incomeKROS Net marginKROS Gross profitKROS Gross marginKROS Operating incomeKROS Operating cash flowKROS Free cash flowKROS Capital expendituresKROS Return on equityKROS Stock buybacksKROS Dividends paidKROS Total assetsKROS Total liabilitiesKROS Shareholders’ equityKROS overview →